Oncodrex
Oncodrex
  • Home
  • About Us
    • Mission
    • Leadership
    • Scientific Advisors
  • Our Technology
  • Contact Us
  • More
    • Home
    • About Us
      • Mission
      • Leadership
      • Scientific Advisors
    • Our Technology
    • Contact Us
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • About Us
    • Mission
    • Leadership
    • Scientific Advisors
  • Our Technology
  • Contact Us

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Targeted therapies for triple negative breast cancer

Oncodrex is developing targeted therapies for hard to treat metastatic cancers such triple negative breast cancer (TNBC). The company has identified unique molecular signatures in metastatic TNBC and is developing small molecules as drug candidates against this signature. This unique molecular signature also has allowed the company to develop a companion diagnostic to select responders to its TNBC drug candidate, an attractive component in a drug development program

Copyright © 2024 Oncodrex - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept